This is an opinion item.
| Author(s)
|
Martin Feldstein
|
| Source
|
The Wall Street Journal
|
| Date
|
August 18, 2009
|
| URL
|
http://online.wsj.com/article/SB10001424052970204683204574358233780260914.html
|
| Quote
|
|
"In the British national health service, a government agency approves only those expensive treatments that add at least one Quality Adjusted Life Year (QALY) per £30,000 (about $49,685) of additional health-care spending. If a treatment costs more per QALY, the health service will not pay for it. The existence of such a program in the United States would not only deny lifesaving care but would also cast a pall over medical researchers who would fear that government experts might reject their discoveries as "too expensive."
|
|
|
Add or change this opinion item's references
This item argues against the position Act should be passed on the topic Patient Protection and Affordable Care Act.
